Advancing mass spectrometry technologies: an interview with Neil Walsh

Neil WalshNeil Walsh received his BSc in Chemistry, and MSc in Pharmaceutical Analysis from Glasgow Caledonian University (UK) and the University of Strathclyde (Glasgow, UK) respectively. He has over 5 years’ experience as a bioanalytical Research Scientist at Aptuit (Edinburgh, United Kingdom) and Tepnel Scientific Services (Glasgow, United Kingdom), and a further 5 years’ in Account Management at both Agilent Technologies (CA, USA) and PerkinElmer (MA, USA). Neil joined SCIEX (MA, USA) in 2013 as a Senior Sales Representative and is currently the Global Marketing Manager for Pharma where he oversees the development of all pharma marketing activity.


1 Could you briefly introduce yourself and your institution? [Time – 00:35]
2 SCIEX recently announced the launch of the new Acoustic Ejection Mass Spectrometry technology. Could you describe how this technology works and what sets it apart from other mass spectrometry technologies? [Time – 01:08]
3 SCIEX also launched the Triple Quad 5500+ LC–MS/MS system – QTRAP ready. What is unique about this instrument and how is it able to deliver high data confidence? [Time – 05:06]
4 The final system that was introduced was the TripleTOF 6600+ LC–MS/MS with scanning SWATH acquisition and OneOmics in the SCIEX cloud. How is this latest model an improvement on previous TripleTOF systems released by SCIEX? [Time – 07:00]
5 Why are technological advancements so important in progressing our scientific knowledge? [Time – 08:42]
6 Looking to the future, what new instrumentation and/or technologies can we expect to see from SCIEX in the next few years? [Time – 10:27]